Castle Biosciences Inc (CSTL)

Castle Biosciences - Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma’si31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB

PROFOUND MEDICAL CORP. (PROF)

(85% Positive) PROFOUND MEDICAL CORP. (PROF) Announces Enrollment Update for balanced Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment